For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: http://mycme.com/courses/the-cognitive-side-of-major-depressive-disorder-10221 Summary Despite significant improvements in mood symptoms, many patients with MDD continue to experience persistent residual symptoms—particularly cognitive impairments—that hinder full functional recovery. In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Roger McIntyre discuss the often-overlooked role of cognitive dysfunction in MDD recovery, highlighting how these impairments correlate strongly with reduced workplace productivity, social withdrawal, and elevated relapse risk, ultimately impeding long-term outcomes. Their conversation provides listeners with an in-depth understanding of the presentation of cognitive impairment and residual symptoms in MDD, as well as strategies to foster resilience, enhance patient engagement, and promote functional recovery. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Recognize the clinical significance of residual symptoms in MDD, with a focus on cognitive impairment, and their impact on patient functioning and treatment outcomes This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology). Summary of Individual Disclosures Please review faculty and planner disclosures here. Disclosure of Commercial Support This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
